Foghorn Therapeutics Inc. (FHTX) Stock Score, Valuation & Financial Research
Foghorn Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for FHTX
Foghorn Therapeutics Inc. currently has a Wall Street Score of 29/100. The stored market price is $4.17. Its financial score is 12/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Foghorn Therapeutics Inc. does
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further d
FHTX financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $4.17
- Market capitalization:
- $244.8M
- Revenue:
- $36.7M
- Net income:
- $-64.6M
- Free cash flow:
- $-86.1M
- Cash:
- $68.1M
- Total debt:
- $43.1M
- EPS:
- -0.99
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 18/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-86.1M, showing cash burn in the current stored period.
- The balance sheet shows $68.1M of cash versus $43.1M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.1 points: FHTX decreased 0.1 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research FHTX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.